Lightstone Ventures related stories
All articles and analysis
Lightstone Ventures raises $375m for third fundLightstone Ventures has closed its third fund at $375 million.
- Lightstone Ventures amasses $375m for third fund
Lightstone Ventures has closed its third fund at $375 million.
Lightstone Ventures targets $350m for third fundLightstone Ventures is seeking to raise $350 million for its third fund, according to an SEC filing.
- Locanabio pulls in $100m Series B
Locanabio Inc, an RNA-targeting gene therapy company, has raised $100 million in Series B financing.
Tallac Therapeutics rallies $62m Series ABurlingame, California-based Tallac Therapeutics Inc, a biopharmaceutical company focused on fighting cancer, has raised $62 million in Series A financing.
- Catamaran Bio gathers $42m
Cambridge, Massachusetts-based Catamaran Bio, Inc, a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer, has raised $42 million in financing.
- Gilead Sciences to invest $300m in VC-backed Tizona Therapeutics
Gilead Sciences Inc has agreed to invest $300 million in Tizona Therapeutics, a clinical-stage immunotherapy company.
- VC-backed ALX Oncology goes public
Burlingame, California-based ALX Oncology Holdings Inc, a immuno-oncology company, has raised $161.5 million for its IPO after pricing its 8.5 million shares at $19 per share.
- Cerevance scores $45m Series B
Cerevance, a private drug discovery and development company focused on brain diseases, has raised $45 million in Series B financing.
- Roche completes Promedior acquisition
Roche has closed its previously announced acquisition of Lexington, Massachusetts-based Promedior, a biotech company.